---
layout: post
title: "Advancing the Development of Pediatric Therapeutics (ADEPT) 10: Addressing Challenges in Neonatal Product Development-Leveraging Rare Disease Frameworks; Public Meeting"
date: 2026-02-04 21:49:23 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-18273
original_published: 2025-09-22 00:00:00 +0000
significance: 8.00
---

# Advancing the Development of Pediatric Therapeutics (ADEPT) 10: Addressing Challenges in Neonatal Product Development-Leveraging Rare Disease Frameworks; Public Meeting

**Published:** February 04, 2026 21:49 UTC
**Source:** Federal Register
**Original Published:** September 22, 2025 00:00 UTC
**Document Number:** 2025-18273

## Summary

The Food and Drug Administration (FDA or we) is announcing the following public workshop entitled "Advancing the Development of Pediatric Therapeutics (ADEPT) 10: Addressing Challenges in Neonatal Product Development--Leveraging Rare Disease Frameworks." The aim of the public workshop is to discuss common challenges in neonatal and rare disease product development and identify opportunities to leverage rare disease product development frameworks in the neonatal product development space.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/09/22/2025-18273/advancing-the-development-of-pediatric-therapeutics-adept-10-addressing-challenges-in-neonatal)
- API: https://www.federalregister.gov/api/v1/documents/2025-18273

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
